Ellen Sheets

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Sequre Dx, Inc. is a genomics intelligence company that focuses on advancing on-target gene editing and cell therapies from discovery to patient. The company is based in Waltham, MA. The company offers preclinical platforms for the biopharma industry, including diagnostic assays and bioinformatic analytics that solve preclinical off-target evaluation needs. Sequre Dx aims to make gene editing and cell therapies suitable for all patients who would benefit from these life-saving technologies. The CEO of the company is Ellen E. Sheets.

CSA Medical, Inc. develops endoscopic cryoablation systems. It provides spray cryotherapy medical device solutions that improve patient outcomes, simplify procedures, and reduce the cost of healthcare. The company was founded by Lloyd Shue, Timothy E. Askew and Frank Majerowicz in 1985 and is headquartered in Lexington, MA.

Tech Council of Maryland, Inc. provides membership association services for technology and life science communities. The firm serves the advanced technology and biotechnology communities. The company was founded in 1986 and is headquartered in Rockville, MD.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Cytyc Corp. manufactures and markets medical diagnostic applications. The company is headquartered in Marlborough, MA.